AI-enabled drug discovery platform
Target-based predictive screening for small-molecule candidate prioritization.
PreditX® is Pharmaeconomica’s cloud-native AI discovery platform designed to support target-based predictive screening, developability triage, consensus prediction reports, and candidate prioritization.
Platform focus
Predict. Filter. Prioritize. Decide.
PreditX® is built around a practical discovery question: which molecules should move forward before experimental resources are committed?
Brand architecture
PreditX® is the platform. Pharmaeconomica is the decision-science company behind it.
Pharmaeconomica combines HEOR, market access, predictive modeling, evidence generation, and AI-enabled discovery. PreditX® extends that same predictive decision-science approach into early drug discovery.
Pharmaeconomica
Life sciences decision science
Evidence, value, access, predictive modeling, strategy, and platform-enabled innovation.
PreditX®
AI discovery platform
Target-based predictive screening, candidate prioritization, and computational discovery workflows.
Platform capabilities
Built to support earlier, more informed discovery decisions.
PreditX® is not positioned as a replacement for experimental validation. It is designed to help teams prioritize which compounds, hypotheses, or libraries deserve further attention.
Target-based predictive screening
PreditX® supports target-focused compound prioritization by using bioactivity data and predictive modeling to help identify promising small-molecule candidates.
Bioactivity prediction
The platform is designed to support prediction of compound activity against selected biological targets, helping users prioritize candidates before costly experimental validation.
ADMET and developability triage
PreditX® supports early filtering based on developability considerations, helping users identify potential pharmacokinetic, toxicity, and drug-likeness risks before advancing candidates further.
Consensus prediction reports
The platform supports interpretation by summarizing predictive outputs into structured reports that help guide decision-making.
Candidate prioritization
PreditX® helps users compare and prioritize molecules based on predicted performance, risk, and strategic relevance.
Generative AI expansion
Generative AI is being developed as an expansion around the predictive core, with the aim of supporting de novo molecular design workflows.
Workflow
From target selection to candidate prioritization.
The platform is structured around practical discovery decisions: selecting a target, preparing data, building models, screening compounds, and interpreting predictions.
Select a biological target
The user starts with a protein target or target identifier relevant to a disease area or research hypothesis.
Retrieve and prepare data
The platform supports structured retrieval and preparation of bioactivity data from public experimental databases such as ChEMBL.
Train predictive models
Machine learning models are trained and evaluated to support prediction of compound activity and prioritization.
Screen candidate molecules
The platform can be used to evaluate external or proprietary compound libraries and identify higher-priority candidates.
Interpret and prioritize
Predictions are translated into decision-support outputs that help researchers decide which compounds deserve further attention.
Who it is for
Designed for teams that need better early discovery prioritization.
PreditX® is relevant when teams have targets, compound ideas, external libraries, or early discovery hypotheses and need a more structured way to prioritize next steps.
Interested in PreditX® for candidate prioritization or discovery strategy?
Contact Pharmaeconomica to discuss how PreditX® or our AI-enabled discovery strategy services can support your target, compound library, research program, or innovation pipeline.
info@pharmaeconomica.com